SynthesisJournal of cellular and molecular medicine2025
Circulating Proteomics and Risk of Atrial Fibrillation: A Systematic Review of Cohort Studies.
Synthesis in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From polygenic risk to digital twins: the future of personalised cardiovascular medicine.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Atrial fibrillation (AF) is a common arrhythmia associated with significant morbidity and adverse outcomes. High-throughput proteomics offers a promising approach for identifying circulating biomarkers to improve AF risk stratification. This systematic review evaluated cohort studies published from 2010 to 2024 that employed proteomic approaches to investigate associations between circulating proteins and AF incidence. Studies were screened using predefined criteria, and proteins significantly associated with AF in fully adjusted models were extracted. Bioinformatics analyses, including pathway enrichment and protein-protein interaction (PPI) network mapping, were conducted to characterise the implicated biological processes. Proteins reproducibly associated with AF across studies were further evaluated through drug target annotation and assessed for potential causal relationships using Mendelian randomisation (MR). In total, 111 proteins were identified across nine cohorts, with significant enrichment in pathways related to extracellular matrix organisation and cell adhesion. PPI analysis identified interleukin-6, matrix metalloproteinase-2 and C-reactive protein as central network hubs. Thirteen proteins were reproducible across at least two studies, with NT-proBNP consistently reported in eight cohorts, supporting its role as a robust and reliable biomarker of AF risk. Drug target analysis showed that four proteins-ANGPT-2, adrenomedullin, GDF15 and PLAUR-are currently under clinical investigation. MR analysis did not confirm causal associations between these proteins and AF, suggesting they may reflect disease-related processes rather than directly drive AF onset. This review highlights reproducible proteomic biomarkers and their functional networks in AF, providing a foundation for future studies focused on biomarker-guided prevention and therapeutic development. Trial Registration: PROSPERO number: CRD420251063038.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.